Explore the vast range of titles available.

\"In The Dashboard Book, the authors will lay out a variety of examples of successful dashboards so that the reader can find a scenario that closely matches what he or she is tasked with visualizing\"-- Provided by publisher.

\"Tips, techniques, and trends on harnessing dashboard technology to optimize business performance In Performance Dashboards, Second Edition, author Wayne Eckerson explains what dashboards are, where they can be used, and why they are important to measuring and managing performance. As Director of Research for The Data Warehousing Institute, a worldwide association of business intelligence professionals, Eckerson interviewed dozens of organizations that have built various types of performance dashboards in different industries and lines of business. Their practical insights explore how you can effectively turbo-charge performance-management initiatives with dashboard technology. Includes all-new case studies, industry research, news chapters on \"Architecting Performance Dashboards\" and \"Launching and Managing the Project\" and updated information on designing KPIs, designing dashboard displays, integrating dashboards, and types of dashboards. Provides a solid foundation for understanding performance dashboards, business intelligence, and performance management. Addresses the next generation of performance dashboards, such as Mashboards and Visual Discovery tools, and including new techniques for designing dashboards and developing key performance indicators. Offers guidance on how to incorporate predictive analytics, what-if modeling, collaboration, and advanced visualization techniques. This updated book, which is 75% rewritten, provides a foundation for understanding performance dashboards, business intelligence, and performance management to optimize performance and accelerate results.\"--

We assessed cost–effectiveness of insertable cardiac monitors (ICMs) in a US cryptogenic stroke population. We modelled lifetime costs and quality-adjusted life years for three monitoring strategies post cryptogenic stroke: ICM starting immediately, ICM starting after Holter monitoring (delayed ICM) and standard of care involving intermittent ECG and Holter monitoring. Patient characteristics and detection efficacy were based on the CRYSTAL-AF trial. AF detection altered the modelled anticoagulation therapy and subsequent stroke and bleed risks. Immediate ICM was found to be cost-effective versus standard of care and cost-saving versus delayed ICM. Results were robust to sensitivity analyses. ICMs are a cost-effective diagnostic tool for the prevention of recurrent stroke in a US cryptogenic stroke population. When patients have a stroke with no identifiable cause, there is a chance that it was caused by an abnormal heart rhythm called atrial fibrillation (AF). If a patient is found to have AF, their risk of having another stroke is much higher and their doctor will usually try to prescribe a blood thinner to prevent further strokes. Guidelines recommend that blood thinners are only prescribed after the presence of AF is confirmed. In the absence of AF they increase bleed risk without clear benefits. The standard way to diagnose AF after a stroke, is to check the patient’s heart rhythm using an ECG and – sometimes but not always – to have the patient wear an external ECG monitor at home. Insertable cardiac monitors (ICMs) are a new alternative to this – they are inserted under the skin on the patient’s body by a minor surgical procedure – and record data on the heart continuously, for several years if required. ICMs are better at finding AF than standard methods and as a result they should help to prevent more strokes in the long run. They have a higher upfront cost because the devices and the minor operation must be paid for and there are also costs for the regular check-ups to review data from the ICM. This project aimed to determine whether ICMs are a good investment for the US healthcare system to detect AF in patients who have had a stroke with no identifiable cause. We did this using an economic model that took into account all possible healthcare costs related to the care of this population and their condition and predict what might be expected to happen given the more complete AF detection that ICMs can provide. The results of the model suggest that although ICMs cost more to administer than standard care without an ICM, they are likely to increase the length and quality of life that is preserved by preventing additional strokes. These benefits are highly valued within the US healthcare system, meaning ICMs are considered cost-effective. An economic analysis developed in the US healthcare setting has found that insertable cardiac monitors are a cost-effective way to detect atrial fibrillation in patients presenting with cryptogenic stroke.

Yuhan Zeng,1 Danna Jiang,2 Lei Guo,1 Yizhang Chen,1,2 Jialu Weng,3 Xiaohan Liu,4 Sunting Qin,1 Mengyu Kong,1 Ziye Zhou,3,5 Xiuhua Zhang6 1Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 3Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 4Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People’s Republic of China; 5Clinical Research Office, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 6Clinical Trial Institution Office, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of ChinaCorrespondence: Xiuhua Zhang, Clinical Trial Institution Office, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Street, Ouhai District, Wenzhou City, 325000, People’s Republic of China, Tel +86 577 55579593, Email Wzzhangxiuhua@126.com Ziye Zhou, Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation & Clinical Research Office, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Street, Ouhai District, Wenzhou City, 325000, People’s Republic of China, Tel +86 577 55579593, Email redd88@163.comPurpose: To evaluate the efficacy and cost-effectiveness of entecavir (ETV) versus tenofovir amibufenamide (TMF) in patients with chronic hepatitis B.Patients and methods: In this retrospective study, patients diagnosed with chronic hepatitis B between January 2022 and June 2024 were screened. Those receiving ETV as first-line therapy were 1:1 propensity score-matched to TMF recipients. The primary endpoint was HBV-DNA negativity conversion at week 48.Results: Of 50,645 screened patients, 182 met eligibility criteria (TMF, n=91 [48 HBeAg-positive, 43 HBeAg-negative]; ETV, n=91 [36 HBeAg-positive, 55 HBeAg-negative]). HBeAg status was balanced between groups (P = 0.074). At week 48, HBV-DNA negativity was 54.95% for TMF and 76.92% for ETV (P = 0.002; OR 95% CI, 0.193– 0.693). Among HBeAg-negative patients, ETV achieved significantly higher negativity at week 24 (P = 0.028) and week 48 (P = 0.041); subgroup findings are exploratory. Treatment costs over 48 weeks were $14060.62 for TMF and $13334.70 for ETV, largely due to national health insurance coverage of ETV. The ICER of TMF versus ETV was -36.28, indicating ETV is more cost-effective. The substantial cost difference is primarily attributable to ETV being covered by national health insurance. Adverse event rates were comparable between the two drugs, indicating similar safety profiles.Conclusion: ETV showed better virologic response and lower drug-related costs than TMF in this single-center retrospective study, especially in HBeAg-negative patients. Further validation in multicenter prospective studies is needed.Plain Language Summary: Question: Comparative efficacy of entecavir (ETV) versus tenofovir amibufenamide (TMF) and their cost-effectiveness in antiviral therapy for patients with chronic hepatitis B (CHB): which treatment regimen is more advantageous in terms of clinical outcomes and economic value?Findings: In this retrospective cohort study that includes 182 patients with CHB, ETV demonstrated significant advantages in terms of both efficacy and cost-effectiveness compared to TMF, with better clinical outcomes and higher economic value.Meaning: These results suggest that ETV may be considered a potentially preferred antiviral regimen for patients with CHB; however, findings should be interpreted cautiously due to the retrospective design and limited sample size.Ethical approval: This study has been formally approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University, ensuring that the study design, implementation process, and data handling all comply with medical ethical standards and relevant laws and regulations. In addition, this study has been registered in the platform of China Clinical Trial Registry Center, registration number: ChiCTR2500097387.Keywords: hepatitis B, tenofovir amibufenamide, entecavir, efficacy, cost-effectiveness evaluation

Machine generated contents note: Introduction Part I A Strong Foundation Chapter 1 Data Visualization: A Primer Part II The Scenarios Chapter 2 Course Metrics Dashboard Chapter 3 Comparing Individual Performance with Peers Chapter 4 What-If Analysis: Wage Increase Ramifications Chapter 5 Executive Sales Dashboard Chapter 6 Ranking by Now, Comparing with Then Chapter 7 Are We On Pace to Reach Our Goals? Chapter 8 Multiple Key Performance Metrics Chapter 9 Power Plant Operations Monitoring Chapter 10 Showing Year-to-Date and Year-over-Year at the Same Time (YTD and YOY) Chapter 11 Premier League Player Performance Metrics Chapter 12 RBS 6 Nations Championship Match Performance Analysis Chapter 13 Web Analytics Chapter 14 Patient History Analysis of Recent Hospital Admissions Chapter 15 Hospitality Dashboard for Hotel Management Chapter 16 Sentiment Analysis: Showing Overall Distribution Chapter 17 Showing Sentiment with Net Promoter Score Chapter 18 Server Process Monitoring Chapter 19 Big Mac Index Chapter 20 Complaints Dashboard Chapter 21 Hospital Operating Room Utilization Chapter 22 Showing Rank and Magnitude Chapter 23 Measuring Claims across Multiple Measures and Dimensions Chapter 24 Showing Churn or Turnover Chapter 25 Showing Actual versus Potential Utilization Chapter 26 Health Care Provider Productivity Monitoring Chapter 27 Telecom Operator Executives Dashboard Chapter 28 The Economy at a Glance Chapter 29 Call Center Part III Dashboards in the Real World Chapter 30 Want to Engage People? Make Your Dashboards Personal Chapter 31 Visualizing Time Chapter 32 Beware the Dead-End Dashboard Chapter 33 The Allure of Red and Green Chapter 34 The Allure of Pies and Donuts Chapter 35 Clouds and Bubbles Chapter 36 A journey into the unknown Index

Heterogeneous missile swarm employs different kinds of missiles to work cooperatively for systematic warfare, which attract much attention in recent years. In order to effectively calculate and evaluate the systematic fighting capacity of heterogenous missile swarm in different scenarios, a systematic modeling and effectiveness evaluation framework is proposed in this paper. Firstly, the combat loop is defined, where the task assignment between missiles and targets is carried out using the contract net auction algorithm. Then the systematic model of heterogeneous missile swarm is constructed in terms of Observation-Orientation-Decision Action(OODA) loop network. Finally, the uncertain self-information method is used to calculate the system’s effectiveness. It can be seen from the results of the engineering example that the framework fully considers the whole process of the combat system, which can comprehensively and effectively evaluate the system effectiveness of the heterogeneous missile swarm system.